NanoViricides, Inc. Files Annual Report - Reports Having Sufficient Funds for Current Goals and for Advancing Its Robust Drug Pipeline

Published: Oct 16, 2012

WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTCBB: NNVC) (the "Company"), reports that it has filed its financial year end annual report (Form 10-K) with the Securities and Exchange Commission (SEC) in a timely manner on Monday, October 15. The report can be accessed at the SEC website (http://www.sec.gov/Archives/edgar/data/1379006/000114420412056152/v325626_10k.htm). The Company estimates that the cash in hand at year end is sufficient for an additional up to eighteen months or more of operational expenses at the current rate. The Company also believes that it now has sufficient financing to advance its drug pipeline further into the Food and Drug Administration (FDA) approval process.

Back to news